Considering that SGLT2 inhibitors are often prescribed together with metformin, this suggests that the SGLT2 inhibitors may have improved prostate cancer hormone therapy treatment outcomes via pathways other than glucose control, consistent with previous genetic findings. Subgroup analyses comparing dapagliflozin and empagliflozin did not reveal substantial differences in their associations with prostate cancer outcomes (Table 2 and eFigure 7 in Supplement 1). This evidence concerns the gene SLC5A2 and prostate carcinoma.